Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers

Category Primary study
JournalCancer Research
Year 2019
This article has no abstract
Epistemonikos ID: ce66e10857dbf66033fce0cd587ee4f973f86a6d
First added on: Feb 11, 2025